Business
Course of Gubra A/S' Extraordinary General Meeting Regarding Extraordinary Dividend
HORSHOLM, DENMARK / ACCESS Newswire / June 27, 2025 / On Friday, 27 June 2025 at 12:00 am (CEST), an extraordinary general meeting of Gubra A/S (CPH:GUBRA) (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 ...
About this update from Gubra A/s
[{"type":"text","content":"HORSHOLM, DENMARK / ACCESS Newswire / June 27, 2025 / On Friday, 27 June 2025 at 12:00 am (CEST), an extraordinary general meeting of Gubra A/S (CPH:GUBRA) (the "Company") was held at the Company's registered address Hørsholm Kongevej 11B, DK-2970 Hørsholm.","length":271,"tagName":"p"},{"type":"text","content":"The only item on the agenda was a resolution to approve a distribution of extraordinary cash dividends to the Company's shareholders in the amount of DKK 1 billion, corresponding to DKK 61.2 per share of a nominal value of DKK 1.","length":233,"tagName":"p"},{"type":"text","content":"The general meeting approved the distribution of extraordinary cash dividends to the Company's shareholders as presented in the notice convening the general meeting.","length":169,"tagName":"p"},{"type":"text","content":"Further details about the distribution of the dividend were included in the notice convening the general meeting announced on 3 June 2025.","length":138,"tagName":"p"},{"type":"text","content":"Contacts at GubraMedia: Sofia Pitt Boserup, [email protected], +45 4188 9586Investors: Kristian Borbos, [email protected], +45 3080 8035","length":128,"tagName":"p"},{"type":"text","content":"About GubraGubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 270 employees and in 2024 revenue of DKK 266 million. See www.gubra.dk for more information.","length":787,"tagName":"p"},{"type":"text","content":"AttachmentsCOURSE OF GUBRA A/S' EXTRAORDINARY GENERAL MEETING REGARDING EXTRAORDINARY DIVIDEND","length":99,"tagName":"p"},{"type":"text","content":"SOURCE: Gubra","length":13,"tagName":"p"},{"type":"text","content":"View the original press release on ACCESS Newswire","length":50,"tagName":"p"}]